{"success":true,"data":{"pressRelease":{"id":"113996","rtpr_id":"nGNE3wJfNl","ticker":"SILO","exchange":"NASDAQ","all_tickers":["SILO"],"title":"Silo Pharma Granted European Patent Covering Novel PTSD Therapy","author":"Globe Newswire","published_at":"2026-08-10T12:15:00.207Z","article_body":"Patent strengthens global IP protection for novel treatment approach designed\nto prevent stress-induced psychiatric disorders before symptoms develop\n\nSARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO)\n(“Silo” or “the Company”), a managed AI agent platform and\ndevelopmental-stage biopharmaceutical company focused on novel therapeutics\nand drug delivery systems, today announced that the European Patent Office\n(EPO) has granted a patent covering the preventative approach of its lead\ncandidate SPC-15, a novel intranasal, nose-to-brain treatment targeting\npost-traumatic stress disorder (PTSD) and stress-induced affective disorders.\nThe Company has an exclusive license for the European patent from Columbia\nUniversity.\n\nThe granted patent, European Patent No. EP3952852, “Prophylactic Efficacy of\nSerotonin 4 Receptor Agonists Against Stress,” covers methods of preventing\nstress-induced fear, depressive-like behavior and associated affective\ndisorders by administering selected serotonin 4 (5-HT4) receptor agonists\nahead of a stressor such as potential extreme stress exposure.\n\n“We continue to strengthen the powerful intellectual property moat around\nSPC-15’s technology—a differentiated approach to PTSD treatment that\ntargets pathways associated with stress resilience rather than relying solely\non symptom management after PTSD has developed,” said Eric Weisblum, Chief\nExecutive Officer of Silo Pharma. “We are pleased with the EPO’s decision\nrecognizing the novelty of this preventative approach and extending important\npatent protection for SPC-15 in the European market. We believe the ability to\nintervene before exposure to acute trauma could represent an entirely new\nparadigm for protecting individuals at high risk of developing PTSD and other\nstress-related disorders.”\n\nThe new European patent further expands the intellectual property portfolio\nsupporting SPC-15 and complements patent protection granted and pending in\nfive other major global markets.\n\nSilo holds an exclusive license agreement with Columbia University to further\ndevelop, manufacture, and commercialize SPC-15 globally.\n\nAbout Silo Pharma, Inc.\n\nQwikAgents, Silo Pharma's wholly owned artificial intelligence subsidiary, is\na managed AI agent platform that delivers dedicated autonomous agents for\nresearch, content generation, scheduling, and workflow automation — each\nrunning in a persistent environment with proprietary smart-routing across\nmultiple AI models. The subsidiary reflects Silo's strategy to expand into\nhigh-growth technology markets while continuing to advance its core\nbiopharmaceutical pipeline. qwikagents.com\n(https://www.globenewswire.com/Tracker?data=1DdFiXEWGl8pgXiATtjfyKQ0IjjwHaMjZPiZmWs6TmOQUOmlYo3QEKaOIXAmNqF6ObVzk77xBkkWp7BEj_aZz9KrYWWmacJak-mDKSQZorzJr33FrxLulcmNjUy71BbbgcuWTR-8eVwFblhGmVTWqqs_hvWm2LtUWc854TJTQwDbt3_NRmnC6O0uuVzbQ9vMgbl479zU78YomyUXmrS4bF9h2tuEBeIfFTJg8tn3Z80=)\n\nSilo Pharma is a diversified developmental-stage biopharmaceutical company\nwith a therapeutic focus on addressing underserved conditions, including\nstress-induced psychiatric disorders, chronic pain, and central nervous system\n(CNS) diseases. The Company’s portfolio includes innovative programs such as\nSPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and\nchronic pain, and a preclinical asset targeting Alzheimer’s disease.\nSilo’s research is conducted in collaboration with leading universities and\nlaboratories. silopharma.com\n(https://www.globenewswire.com/Tracker?data=gm94fgbL41QIsPKIgtO8ohixriMDCk_MgX3Vh3OVJuDI0yqPtwB6HG4_rg2d6LruHe8T9XB4Ucjyv18dT-0H4tvvL69YUTE6AvlKK3ZZVIn2X9K3pId64MQnwJ3OtdCV6ZP9o40XJBN3wLoMOQep1Jd6IFEFioIoKPtsMs4L5pGmIvvw3IStoHpJlHjTwiYsF-9oDCEoC69Cg5CR-3rj-B4tCK0SsPa1byJKxAjFOnldX-DxKuCSweDz13Ix7EulZwVVlqQEDAjMa6_03Mbynt6bHr5rYOv93AU1vNG5-20zjwDniZklDPssHNtEq4nVQX0HNAgyu1bK7PxUjngvXTAGEGFJQZCEQIOFxlRtrE0S1WcqcLA_sUSx9hFhG8SkQmmeYY9lfiiM8XFCgcO9UI5nFmOEjARhCkWCII7AKhLvycckKSuwjnDAwR4DdobK1yUzS1fN7RCQw3YgdQLFUz6H2KfcSrtqfPxA_U5f3Y15Mp4Vvb0rSp52ev21-tvN5iOBnT1I7u5yw75BjyRlX2wEWUFK01VIrqj_bXSsZdTFv0Kn7XdvGQF0nM5M285Q6S19QeKpxsOtwuiL54PMVgFX3flCYfoqsK_A4UXyaUQu106iTzC55UY8XNouW60dmyH_BiIleqaGYGCWI8Qrgsi3FnP3iZOYydGMXnhRH2yZmgKXTf63uyv-xn60sh3Xe2wEzWBgJhKKiJobJn4kJJ3gYyHv6gLNqRYzCDf7EhO9DN_PgTH2NzfPNODvLr0TU6zbwMT1CHHB98LdhULitIergGLafFJNbe1AK34-JtH1fckkQkAR8xf9_1oE3rkMH2cAbxVFMGfrwxKzm0Me2YwsMsG2grxDk9YG0lcoHgwCNAkvhyXzH2aJoUs6TDoxDMU4O0_HCjsAkQAZ9rzDkwj11Ct3ZGSWn8-GVH_uAnMVI06nohjoZhCh21GPyBXa6N3PlOtk-TYaX2JYIYu88VMJk06LWBcIQIg2vSW6-C-vY3rq4s4XLmC73nuCDNZm)\n\nForward Looking Statements\n\nThis news release contains “forward-looking statements” within the meaning\nof the “safe harbor” provisions of the Private Securities Litigation\nReform Act of 1995. These statements are identified using words “could”,\n“believe”, “anticipate”, “intend”, “estimate”, “expect”,\n“may”, “continue”, “predict”, “potential”, and similar\nexpressions that are intended to identify forward-looking statements. Such\nstatements involve known and unknown risks, uncertainties, and other factors\nthat could cause the actual results of the Company to differ materially from\nthe results expressed or implied by such statements, including statements\nabout changes to anticipated sources of revenues, future economic and\ncompetitive conditions, difficulties in developing the Company’s technology\nplatforms, retaining and expanding the Company’s customer base, fluctuations\nin consumer spending on the Company’s products and other factors.\nAccordingly, although the Company believes that the expectations reflected in\nsuch forward-looking statements are reasonable, there can be no assurance that\nsuch expectations will prove to be correct. The Company disclaims any\nobligations to publicly update or release any revisions to the forward-looking\ninformation contained in this press release, whether as a result of new\ninformation, future events, or otherwise, after the date of this press release\nor to reflect the occurrence of unanticipated events except as required by\nlaw.\n\nContact\n\n(800) 705-0120\ninvestors@silopharma.com","article_body_html":"","raw_payload":{"data":{"id":"nGNE3wJfNl","title":"Silo Pharma Granted European Patent Covering Novel PTSD Therapy","author":"Globe Newswire","ticker":"SILO","created":"2026-08-10T12:15:00.207Z","tickers":["SILO"],"exchange":"NASDAQ","article_body":"Patent strengthens global IP protection for novel treatment approach designed\nto prevent stress-induced psychiatric disorders before symptoms develop\n\nSARASOTA, FLA., Aug. 10, 2026 (GLOBE NEWSWIRE) -- Silo Pharma (Nasdaq: SILO)\n(“Silo” or “the Company”), a managed AI agent platform and\ndevelopmental-stage biopharmaceutical company focused on novel therapeutics\nand drug delivery systems, today announced that the European Patent Office\n(EPO) has granted a patent covering the preventative approach of its lead\ncandidate SPC-15, a novel intranasal, nose-to-brain treatment targeting\npost-traumatic stress disorder (PTSD) and stress-induced affective disorders.\nThe Company has an exclusive license for the European patent from Columbia\nUniversity.\n\nThe granted patent, European Patent No. EP3952852, “Prophylactic Efficacy of\nSerotonin 4 Receptor Agonists Against Stress,” covers methods of preventing\nstress-induced fear, depressive-like behavior and associated affective\ndisorders by administering selected serotonin 4 (5-HT4) receptor agonists\nahead of a stressor such as potential extreme stress exposure.\n\n“We continue to strengthen the powerful intellectual property moat around\nSPC-15’s technology—a differentiated approach to PTSD treatment that\ntargets pathways associated with stress resilience rather than relying solely\non symptom management after PTSD has developed,” said Eric Weisblum, Chief\nExecutive Officer of Silo Pharma. “We are pleased with the EPO’s decision\nrecognizing the novelty of this preventative approach and extending important\npatent protection for SPC-15 in the European market. We believe the ability to\nintervene before exposure to acute trauma could represent an entirely new\nparadigm for protecting individuals at high risk of developing PTSD and other\nstress-related disorders.”\n\nThe new European patent further expands the intellectual property portfolio\nsupporting SPC-15 and complements patent protection granted and pending in\nfive other major global markets.\n\nSilo holds an exclusive license agreement with Columbia University to further\ndevelop, manufacture, and commercialize SPC-15 globally.\n\nAbout Silo Pharma, Inc.\n\nQwikAgents, Silo Pharma's wholly owned artificial intelligence subsidiary, is\na managed AI agent platform that delivers dedicated autonomous agents for\nresearch, content generation, scheduling, and workflow automation — each\nrunning in a persistent environment with proprietary smart-routing across\nmultiple AI models. The subsidiary reflects Silo's strategy to expand into\nhigh-growth technology markets while continuing to advance its core\nbiopharmaceutical pipeline. qwikagents.com\n(https://www.globenewswire.com/Tracker?data=1DdFiXEWGl8pgXiATtjfyKQ0IjjwHaMjZPiZmWs6TmOQUOmlYo3QEKaOIXAmNqF6ObVzk77xBkkWp7BEj_aZz9KrYWWmacJak-mDKSQZorzJr33FrxLulcmNjUy71BbbgcuWTR-8eVwFblhGmVTWqqs_hvWm2LtUWc854TJTQwDbt3_NRmnC6O0uuVzbQ9vMgbl479zU78YomyUXmrS4bF9h2tuEBeIfFTJg8tn3Z80=)\n\nSilo Pharma is a diversified developmental-stage biopharmaceutical company\nwith a therapeutic focus on addressing underserved conditions, including\nstress-induced psychiatric disorders, chronic pain, and central nervous system\n(CNS) diseases. The Company’s portfolio includes innovative programs such as\nSPC-15 for post-traumatic stress disorder (PTSD), SP-26 for fibromyalgia and\nchronic pain, and a preclinical asset targeting Alzheimer’s disease.\nSilo’s research is conducted in collaboration with leading universities and\nlaboratories. silopharma.com\n(https://www.globenewswire.com/Tracker?data=gm94fgbL41QIsPKIgtO8ohixriMDCk_MgX3Vh3OVJuDI0yqPtwB6HG4_rg2d6LruHe8T9XB4Ucjyv18dT-0H4tvvL69YUTE6AvlKK3ZZVIn2X9K3pId64MQnwJ3OtdCV6ZP9o40XJBN3wLoMOQep1Jd6IFEFioIoKPtsMs4L5pGmIvvw3IStoHpJlHjTwiYsF-9oDCEoC69Cg5CR-3rj-B4tCK0SsPa1byJKxAjFOnldX-DxKuCSweDz13Ix7EulZwVVlqQEDAjMa6_03Mbynt6bHr5rYOv93AU1vNG5-20zjwDniZklDPssHNtEq4nVQX0HNAgyu1bK7PxUjngvXTAGEGFJQZCEQIOFxlRtrE0S1WcqcLA_sUSx9hFhG8SkQmmeYY9lfiiM8XFCgcO9UI5nFmOEjARhCkWCII7AKhLvycckKSuwjnDAwR4DdobK1yUzS1fN7RCQw3YgdQLFUz6H2KfcSrtqfPxA_U5f3Y15Mp4Vvb0rSp52ev21-tvN5iOBnT1I7u5yw75BjyRlX2wEWUFK01VIrqj_bXSsZdTFv0Kn7XdvGQF0nM5M285Q6S19QeKpxsOtwuiL54PMVgFX3flCYfoqsK_A4UXyaUQu106iTzC55UY8XNouW60dmyH_BiIleqaGYGCWI8Qrgsi3FnP3iZOYydGMXnhRH2yZmgKXTf63uyv-xn60sh3Xe2wEzWBgJhKKiJobJn4kJJ3gYyHv6gLNqRYzCDf7EhO9DN_PgTH2NzfPNODvLr0TU6zbwMT1CHHB98LdhULitIergGLafFJNbe1AK34-JtH1fckkQkAR8xf9_1oE3rkMH2cAbxVFMGfrwxKzm0Me2YwsMsG2grxDk9YG0lcoHgwCNAkvhyXzH2aJoUs6TDoxDMU4O0_HCjsAkQAZ9rzDkwj11Ct3ZGSWn8-GVH_uAnMVI06nohjoZhCh21GPyBXa6N3PlOtk-TYaX2JYIYu88VMJk06LWBcIQIg2vSW6-C-vY3rq4s4XLmC73nuCDNZm)\n\nForward Looking Statements\n\nThis news release contains “forward-looking statements” within the meaning\nof the “safe harbor” provisions of the Private Securities Litigation\nReform Act of 1995. These statements are identified using words “could”,\n“believe”, “anticipate”, “intend”, “estimate”, “expect”,\n“may”, “continue”, “predict”, “potential”, and similar\nexpressions that are intended to identify forward-looking statements. Such\nstatements involve known and unknown risks, uncertainties, and other factors\nthat could cause the actual results of the Company to differ materially from\nthe results expressed or implied by such statements, including statements\nabout changes to anticipated sources of revenues, future economic and\ncompetitive conditions, difficulties in developing the Company’s technology\nplatforms, retaining and expanding the Company’s customer base, fluctuations\nin consumer spending on the Company’s products and other factors.\nAccordingly, although the Company believes that the expectations reflected in\nsuch forward-looking statements are reasonable, there can be no assurance that\nsuch expectations will prove to be correct. The Company disclaims any\nobligations to publicly update or release any revisions to the forward-looking\ninformation contained in this press release, whether as a result of new\ninformation, future events, or otherwise, after the date of this press release\nor to reflect the occurrence of unanticipated events except as required by\nlaw.\n\nContact\n\n(800) 705-0120\ninvestors@silopharma.com"},"type":"article","timestamp":"2026-08-10T12:15:00.324068539Z","server_sent_at_ms":1786364100324},"received_at":"2026-08-10T12:15:00.375Z","source_url":"https://www.globenewswire.com/news-release/2026/08/10/3341810/0/en/silo-pharma-granted-european-patent-covering-novel-ptsd-therapy.html"},"analysis":{"id":"102994","press_release_id":"113996","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"operations_update","narrative":"Silo Pharma announced that the European Patent Office has granted a patent covering the preventative approach of its lead candidate SPC-15 for PTSD and stress-induced affective disorders.\n\nThe patent protects methods of preventing stress-induced fear and depressive-like behavior using serotonin 4 receptor agonists administered prior to trauma exposure.\n\nThis milestone strengthens the global IP position for SPC-15 and complements existing protection in five other major markets under an exclusive license from Columbia University.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"European patent granted for lead candidate SPC-15 expands IP protection."},"keyFigures":{"customDimensions":{"patent_number":"EP3952852","protected_markets":"Europe plus five other major global markets"}},"quotedText":"We continue to strengthen the powerful intellectual property moat around SPC-15’s technology—a differentiated approach to PTSD treatment that targets pathways associated with stress resilience rather than relying solely on symptom management after PTSD has developed","namedEntities":{"people":[{"name":"Eric Weisblum","role":"Chief Executive Officer"}],"products":["SPC-15","SP-26"],"companies":[{"name":"Silo Pharma","ticker":"SILO"},{"name":"Columbia University","relationship":"licensor"},{"name":"QwikAgents","relationship":"subsidiary"},{"name":"European Patent Office","relationship":"regulatory body"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"Granting of a European patent for the lead candidate SPC-15 strengthens the company's intellectual property moat in a major market, which is a significant milestone for a developmental-stage biopharmaceutical company."},"tickerRelevance":{"others":[],"primary":"SILO"},"globalImportance":15,"audienceRelevance":10,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"patent_grant","sectorWeight":"biotech"}},"event_type":"operations_update","event_type_secondary":null,"sentiment":"bullish","material_impact_score":3,"narrative":"Silo Pharma announced that the European Patent Office has granted a patent covering the preventative approach of its lead candidate SPC-15 for PTSD and stress-induced affective disorders.\n\nThe patent protects methods of preventing stress-induced fear and depressive-like behavior using serotonin 4 receptor agonists administered prior to trauma exposure.\n\nThis milestone strengthens the global IP position for SPC-15 and complements existing protection in five other major markets under an exclusive license from Columbia University.","key_figures":{"customDimensions":{"patent_number":"EP3952852","protected_markets":"Europe plus five other major global markets"}},"named_entities":{"people":[{"name":"Eric Weisblum","role":"Chief Executive Officer"}],"products":["SPC-15","SP-26"],"companies":[{"name":"Silo Pharma","ticker":"SILO"},{"name":"Columbia University","relationship":"licensor"},{"name":"QwikAgents","relationship":"subsidiary"},{"name":"European Patent Office","relationship":"regulatory body"}],"dollarAmounts":[]},"model_name":"glm-4.7","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-08-10T16:21:53.690Z","global_importance":15,"audience_relevance":10,"importance_components":{"tickerTier":"micro-cap","eventGravity":"patent_grant","sectorWeight":"biotech"}},"durationMs":93146,"modelName":"glm-4.7"}}